What’s New on the Website
Press coverage
Critical Governance, Ethical, and Regulatory Considerations in Deploying AI Solutions and How to Address Them
04.01.26
Press coverage
385+ revenue cycle management companies to know | 2026
03.31.26
Press coverage
AI Can Quickly Become a Confident Liar. Dimensional Insight Explains How to Prevent It.
Click to read the article
02.17.26
Press coverage
20 Marketing Challenges Leaders Are Facing This Year—And How To Solve Them
New Episode of the Knowledge Forum!
- DivePort: Controlling First-Load Behavior with Defaults
- Squashing vs. Diving: Comparing Spectre Flow and Spectre Dive
Watch new episode →
New Episode of the Knowledge Forum!
- DivePort Page Types
- Crosstab: Brand Analysis in NAVO
Watch new episode →
Press release
Dimensional Insight named a Strong Performer in the 2025 Voice of the Customer for Analytics and BI
Distinction in Gartner Report Is Based on Feedback and Ratings from End-User Professionals
Press release
Dimensional Insight Recognized in KLAS 2025 Consistent High Performers Report
Recognition underscores Dimensional Insight’s long-term commitment to trusted partnerships, measurable outcomes, and customer satisfaction in healthcare analytics
12.05.24
New Episode of the Knowledge Forum!
- Using Program Advisor
Watch new episode →
12.01.25
Press coverage
Leveraging Advanced Analytics and AI Tools to Derive Actionable Insights from Complex Healthcare Datasets
News Archive
2025
2024
2023
2022
2021
2020
What Baseball’s New ABS System Can Teach Us About Analytics
Over the past few years Major League Baseball has introduced a number of new rules. For a sport notoriously slow – or even resistant – to making changes, it has been jarring for some fans. Most of the adjustments have been well-received, though, because they have improved the quality of play on the field.
How GLP-1 Drugs Are Impacting Beverage Alcohol Sales
The next disruption in beverage alcohol isn’t coming from a new product—it’s coming from healthcare.
For years, the biggest shifts in beverage alcohol have been driven by consumer preference: premiumization, ready-to-drink cocktails, and more recently, non-alcoholic alternatives.
But a new force is emerging—and it’s fundamentally different. Drugs like Wegovy and Ozempic—part of a class known as GLP-1 receptor agonists—are beginning to influence not just how much people eat, but how much they drink. And for an industry already facing declining volumes, that matters.